V8 Peptides — Engineered Performance
Research Library
TB-500 Preclinical Studies: Fragment vs Thymosin Beta-4
TB-500Comparison

TB-500 Preclinical Studies: Fragment vs Thymosin Beta-4

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do published preclinical studies say about TB-500 and thymosin β4? Most of the literature is on full-length thymosin β4 (43 residues), not on the short fragment that the V8 product consists of. Rat and mouse wound models (including diabetic and aged mice), a keratinocyte migration assay and a cardiac cell-migration study are the main sources, and one wound study also tested the seven-residue actin-binding sequence LKKTETQ directly. This guide separates what was tested in which molecule and model, shows how quantities were reported, and gives the concentration arithmetic as formulas only. It recommends nothing. The TB-500 product page describes the material: a 10 mg lyophilized vial of the Ac-LKKTETQ fragment, formula C38H68N10O14.

Protocol-style questions about TB-500 usually assume that "TB-500" and "thymosin β4" are interchangeable. They are not, and the difference determines which studies are relevant to a bench design. Thymosin β4 is a 43-residue peptide that sequesters actin monomers; the actin-binding region lies in a short central stretch, and the seven-residue segment Ac-LKKTETQ derived from it is what the V8 product page describes. Reading the literature with that in mind turns a vague topic into a short list of precise questions. Compound background is in the TB-500 research overview, and the relationship between the two names is covered in TB-500 vs thymosin beta 4. For laboratory research use only; not for human consumption.

Which molecule was studied?

StudyMolecule testedSystemReported readouts
Malinda and colleagues, 1999Full-length thymosin β4Rat full-thickness dermal wound; keratinocyte migration chamberRe-epithelialization, contraction, collagen deposition, angiogenesis, cell migration
Philp and colleagues, 2003 (Wound Repair Regen)Full-length thymosin β4 and the LKKTETQ sequenceFull-thickness wounds in normal rats, db/db diabetic mice and aged miceWound contracture, collagen deposition, keratinocyte migration
Philp and colleagues, 2003 (FASEB J)Actin-binding site of thymosin β4Angiogenesis and wound modelsRole of the actin-binding sequence in vascular and repair endpoints
Bock-Marquette and colleagues, 2004Full-length thymosin β4Cardiac cells and mouse heartIntegrin-linked kinase activation, cell migration and survival

The fragment sold as TB-500 is the Ac-LKKTETQ sequence. Only some of the work above tested it, and in the wound study the sequence was tested in aged animals. Everything else describes the parent protein. A summary that says "TB-500 was shown to ..." without naming the molecule tested should be traced to the primary paper.

The wound models in detail

Malinda and colleagues (1999) asked whether thymosin β4 enhanced wound healing in a rat full-thickness model. They report that topical or intraperitoneal application increased re-epithelialization by 42% over saline controls at day 4 and by as much as 61% at day 7, that treated wounds contracted at least 11% more by day 7, and that collagen deposition and angiogenesis were increased. In a Boyden chamber assay, keratinocyte migration was stimulated two- to three-fold over medium alone with as little as 10 pg of the peptide, measured after four to five hours. These figures belong to those experiments, with that vehicle, that species and that readout; they are quoted to show how the work was reported, not as quantities to use.

Philp and colleagues (2003) extended the model to impaired healing: db/db diabetic mice and 26-month-old mice. Thymosin β4 in phosphate-buffered saline or in a hydrogel increased wound contracture and collagen deposition in diabetic mice, with no difference in keratinocyte migration because the animals' wounds were almost completely covered by day 8. In aged mice, healing was delayed and thymosin β4 accelerated it, with increases in keratinocyte migration, contracture and collagen deposition. The seven-residue LKKTETQ peptide promoted repair in aged animals to a degree comparable to the parent molecule. The paper also shows how formulation was handled as a variable, comparing saline with hydrogel.

Cardiac work and a different kind of endpoint

Bock-Marquette and colleagues (2004) studied cardiac cells and the mouse heart. They report that thymosin β4 activated integrin-linked kinase, promoted cardiac cell migration and survival, and was associated with improved cardiac outcomes in a mouse injury model. Its relevance for a reader is the shift in mechanism: where the wound papers concentrate on epithelial and matrix endpoints, this one asks about kinase signalling and cell survival. Goldstein, Hannappel and Kleinman (2005) review these and other actions, describing a protein best known as an actin-sequestering molecule that appears to take on additional roles at sites of injury. The review is a good starting point for a laboratory defining a question, since it maps which activities have been attached to which part of the molecule.

Reading study quantities without borrowing them

The primary papers express quantities in different currencies: picograms in a migration chamber, amounts per wound or per animal for topical and intraperitoneal application, and concentrations in a hydrogel or saline vehicle. Record the whole tuple (molecule, system, route, vehicle, unit basis, duration) and keep it together. Three conversions should be avoided. Do not turn an animal figure into a cell concentration. Do not carry a full-length protein figure over to a fragment: the molecular weights differ by roughly a factor of five (the fragment is about 889 Da, the full-length protein is a few thousand), so equal mass is not equal molarity, and the activities differ as well. And do not read a vehicle effect as an active-ingredient effect, since a hydrogel or buffer alone can influence wound closure.

Concentration arithmetic as formulas

For a laboratory stock, define m as the labelled vial mass, V as the diluent volume, MW as the molecular weight and f as net peptide content (1 if unknown; say so).

  • Mass concentration: c = (m × f) ÷ V
  • Molar concentration: C = c ÷ MW
  • Working solution: V₁ = C₂V₂ ÷ C₁
  • Dilution series: Cn = C₀ ÷ dⁿ
  • Mass to moles: n = mass ÷ MW

The product page lists C38H68N10O14, about 889 Da for the free peptide, which makes the fragment small enough that picomole quantities correspond to very small masses. Small peptides adsorb to plastic and glass, so at low concentrations the real amount can be well below the calculated one. Low-binding tubes, carrier protein where the assay allows it and a minimum of transfers limit the loss. The reconstitution calculator carries out the formulas for a chosen vial, and peptide reconstitution volume calculations explains each step. No volume table is given, because the correct volume depends on the experiment.

Handling and storage

The product page states storage at 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light, and lists a sealed clear glass research vial with lyophilized powder. Let the vial reach room temperature before opening, add diluent slowly and swirl gently. Aliquot a held stock into single-use portions and avoid refreezing. Methods for the diluent choice and solution life are in how to reconstitute a lyophilized peptide, how long do reconstituted peptides last and storing research peptides. For blend-specific handling, see BPC-157 and TB-500 blend reconstitution.

On documentation: record the lot received and the documents actually supplied, and verify identity in-house if the result depends on it. The COA library lists what has been published, and TB-500 purity testing explains what to look for. Other materials are in the shop.

Designing a controlled experiment

  • Name the molecule. State fragment or full-length protein, with sequence and source, in the methods.
  • Vehicle and formulation controls. Buffer alone and, if relevant, hydrogel alone.
  • A scrambled or unrelated peptide of similar length. This separates sequence-specific activity from general peptide effects.
  • Sampling days. Match them to wound stages, as in the rat and mouse papers.
  • Blinded measurement. Planimetry and histological scoring are observer dependent.
  • Replication. Independent experiments on different days, with the statistical rule written in advance.

These controls address the most common weakness in secondary summaries: effects attributed to the molecule that the design cannot separate from the carrier or the model.

Quick reference: full-length protein versus fragment

PropertyThymosin β4 (full length)Ac-LKKTETQ fragment (V8 TB-500 page)
Length43 residues7 residues, N-terminally acetylated
Approximate massSeveral thousand DaAbout 889 Da from C38H68N10O14
Actin-binding regionContains it, among other regionsRepresents the actin-binding sequence
Studies discussed hereRat and mouse wound, migration and cardiac workAged-mouse wound study (Philp and colleagues, 2003)
Consequence for designCannot be assumed to represent the fragmentCannot be assumed to represent the protein

Keeping the two columns apart in a notebook prevents the most frequent error in this area, which is quoting a protein result as if the fragment had produced it. A methods section should state which molecule was used, give its sequence and say where the material came from.

Limits of the literature

The papers discussed are from a small number of groups and cover specific models, so replication across laboratories and species matters. Most use the full-length protein, and fragment-specific data are sparser. Endpoints such as re-epithelialization and contracture are measured differently between laboratories, and rodent skin heals mainly by contraction, which limits translation to other species. Cardiac findings come from a different system with different mechanisms. A new bench experiment that states the molecule, includes vehicle and scrambled-peptide controls and is analyzed blind adds information that the existing papers cannot supply.

Frequently asked questions

Is TB-500 the same as thymosin beta 4?

No. Thymosin β4 is a 43-residue protein. The V8 TB-500 product page describes the seven-residue fragment Ac-LKKTETQ derived from its actin-binding region.

Which studies tested the fragment?

The 2003 wound study by Philp and colleagues tested the LKKTETQ sequence in aged mice alongside the full-length protein. Most other studies used full-length thymosin β4.

What models were used?

Rat full-thickness dermal wounds, db/db diabetic mice, aged mice, keratinocyte migration chambers and cardiac cell and mouse heart models.

Does this article give recommended quantities?

No. It reports how studies expressed quantities and gives formulas for stock arithmetic. Study figures belong to their model.

What is the formula on the product page?

C38H68N10O14, about 889 Da for the free peptide.

Why not convert full-length protein figures to the fragment?

The molecular weights differ several-fold, so equal mass is not equal molarity, and the activities of the two molecules are not interchangeable.

How is the vial supplied and stored?

As lyophilized powder in a sealed clear glass research vial, 10 mg, stored at 2–8 °C or −20 °C for long-term holding, protected from heat, moisture and light.

Why do small peptides need low-binding tubes?

Small peptides adsorb to plastic and glass, and the loss is proportionally largest in dilute solutions.

What controls matter most?

Vehicle controls, a scrambled peptide control, blinded measurement and a clear statement of which molecule was used.

Where do I check identity and purity?

On the certificate of analysis where published, through the COA library. Verify identity in-house if the result depends on it.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside the laboratory.

Related reading: History of TB-500 and Thymosin β4 Research, TB-500: Angiogenesis and Cell Migration Assay Guide, TB-500 Laboratory Safety and Handling Guide.

References

  1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004
  2. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  3. Philp D, Badamchian M, Scheremeta B, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x
  4. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje
  5. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
  6. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453(7193):314-321. doi:10.1038/nature07039

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.